Biotech Values

[DewDiligence]

IPXL will reverse-merge into Amneal Pharma—according to WSJ sources:

https://www.wsj.com/articles/impax-laboratories-and-amneal-pharmaceuticals-near-merger-agreement-1508188888

The companies are in advanced negotiations on an all-stock deal that would hand Impax shareholders 25% of a new, publicly traded company and owners of closely-held Amneal the remainder, the people said. The combined company is expected to be worth $6.4 billion, or about $9 billion with debt…

This link-up was alluded to in the WSJ about one month ago. If consummated, the merged company would have the fifth-largest market share in US generic drugs.